Craneware Gets a Painful Growth Reset

Craneware, a healthcare-software company, has faced a significant setback as it reported a sharp decline in revenue and adjusted EBITDA for the year ending June 2027. The company, valued for its potential to be the next Nvidia, now anticipates revenue of around $185 million, down from the previously expected growth. This downturn coincides with regulatory uncertainty surrounding the U.S. 340B drug-pricing market and a recent cyberattack.

The cyberattack, disclosed in July, led to legal, regulatory, and customer concerns, although customer services and core operations remained unaffected. Craneware is still assessing the extent of data affected, notifying customers and regulators, and evaluating potential consequences. The incident has prompted management to adopt a more cautious planning basis for the next three years, focusing on contract renewals, cost control, and cash generation.

Despite these challenges, Craneware's products are deeply integrated into hospital financial workflows, with contracts typically lasting several years and customer retention exceeding 90%. The company has traditionally been attractive due to its dependability in the technology market. However, the recent setbacks have shifted investor focus from potential growth to the company's ability to maintain and defend its existing business.

The 340B market presents a potential recovery lever, but regulatory clarity and the company's ability to adapt its products will be crucial for future growth. With $54.8 million in cash and strong cash conversion, the immediate survival risk is mitigated, but credibility around future growth remains the primary concern for investors.